Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Event-Driven

<p>After weeks of deliberation, the board of <a href="https://www.smartkarma.com/entities/10365" target="_blank" data-smartkarma-citation="entities:10365:1">Sirtex Medical Ltd (SRX AU)</a> has finally decided to enter a binding scheme implementation deed with China-based CDH Genetech Ltd and <a href="https://www.smartkarma.com/entities/15283" target="_blank" data-smartkarma-citation="entities:15283:1">China Grand Pharmaceuticals And Healthcare Hld. Ltd. (512 HK)</a>, or CDH-CGP, at AUD 33.60 per share, valuing the company at around AUD 1.87 billion. This represents a 20% premium to the unchanged AUD 28 per share offer by U.S.-based <a href="https://www.smartkarma.com/entities/7308" target="_blank" data-smartkarma-citation="entities:7308:1">Varian Medical Systems Inc (VAR US)</a>, announced on Jan. 30, and according to management, follows…</p>

After weeks of deliberation, the board of Sirtex Medical Ltd (SRX AU) has finally decided to enter a binding scheme implementation deed with China-based CDH Genetech Ltd and China Grand Pharmaceuticals And Healthcare Hld. Ltd. (512 HK), or CDH-CGP, at AUD 33.60 per share, valuing the company at around AUD 1.87 billion. This represents a 20% premium to the unchanged AUD 28 per share offer by U.S.-based Varian Medical Systems Inc (VAR US), announced on Jan. 30, and according to management, follows…

China Grand Pharmaceutical and Healthcare (512 HK)

China Grand Pharmaceutical and Healthcare

Sirtex Board Deems China Bid Best for Shareholders and Accepts Higher Offer; Adjusting FVE